Data
Lookout
Search
Browse
Diseases
Sponsors
Pipeline Pulse
Weekly Report
Watchlist
Blog
Pricing
Sign In
Home
NCT06492525
Clinical Trial
A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
Unknown
Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2024 (before its estimated October 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to estimate the effect of rifampicin or itraconazole on the single dose PK of ensartinib.
Protocol Amendment History
1 change
critical
Trial status changed: Not Yet Recruiting → Unknown
2026-08-02
Trial Details
NCT Number
NCT06492525
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Conditions
Healthy
Enrollment
36 participants
Start Date
2024-07
Primary Completion
2024-10
(estimated)
Study Completion
2024-12
(estimated)
Updated on ClinicalTrials.gov
2024-07-09